Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model.

Nshimyumukiza L, Duplantie J, Gagnon M, Douville X, Fournier D, Lindsay C, Parent M, Milot A, Giguère Y, Gagné C, Rousseau F, Reinharz D.

Thromb J. 2013 Jul 17;11(1):14. doi: 10.1186/1477-9560-11-14.

2.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
3.

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.

You JH, Tsui KK, Wong RS, Cheng G.

PLoS One. 2012;7(6):e39640. doi: 10.1371/journal.pone.0039640. Epub 2012 Jun 22.

4.

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

McKeage K.

Pharmacoeconomics. 2012 Sep 1;30(9):841-55. doi: 10.2165/11209130-000000000-00000. Review.

PMID:
22734683
5.

Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.

Wouters H, Thijs V, Annemans L.

J Med Econ. 2013;16(3):407-14. doi: 10.3111/13696998.2013.766200. Epub 2013 Jan 22.

PMID:
23320796
6.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM.

Thromb Haemost. 2011 May;105(5):908-19. doi: 10.1160/TH11-02-0089. Epub 2011 Mar 22.

PMID:
21431243
7.

Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.

Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2013 Jul;31(7):551-62. doi: 10.1007/s40273-013-0051-8. Review.

PMID:
23620211
8.

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV.

Thromb Haemost. 2012 Oct;108(4):672-82. Epub 2012 Aug 17.

PMID:
22898892
9.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.

Chevalier J, Delaitre O, Hammès F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

10.

A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.

Sorensen SV, Peng S, Monz BU, Bradley-Kennedy C, Kansal AR.

Pharmacoeconomics. 2013 Jul;31(7):589-604. doi: 10.1007/s40273-013-0035-8.

11.

Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.

Kongnakorn T, Lanitis T, Annemans L, Thijs V, Goethals M, Marbaix S, Wautrecht JC.

Clin Drug Investig. 2015 Feb;35(2):109-19. doi: 10.1007/s40261-014-0253-7.

PMID:
25511639
12.

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, Kansal AR.

Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.

13.

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.

Davidson T, Husberg M, Janzon M, Oldgren J, Levin LÅ.

Eur Heart J. 2013 Jan;34(3):177-83. doi: 10.1093/eurheartj/ehs157. Epub 2012 Jun 24.

PMID:
22733833
14.

Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.

Bergh M, Marais CA, Miller-Jansön H, Salie F, Stander MP.

S Afr Med J. 2013 Feb 15;103(4):241-5. doi: 10.7196/samj.6471.

PMID:
23547700
15.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR.

Heart. 2012 Apr;98(7):573-8. doi: 10.1136/heartjnl-2011-300646.

16.

Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.

Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y.

Cardiovasc Drugs Ther. 2014 Dec;28(6):575-85. doi: 10.1007/s10557-014-6558-1.

PMID:
25319314
17.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

18.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Eckman MH, Rosand J, Greenberg SM, Gage BF.

Ann Intern Med. 2009 Jan 20;150(2):73-83.

PMID:
19153410
19.

Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

Langkilde LK, Bergholdt Asmussen M, Overgaard M.

J Med Econ. 2012;15(4):695-703. doi: 10.3111/13696998.2012.673525. Epub 2012 Mar 22.

PMID:
22397590
20.

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.

Kamel H, Easton JD, Johnston SC, Kim AS.

Neurology. 2012 Oct 2;79(14):1428-34. doi: 10.1212/WNL.0b013e31826d5fe8. Epub 2012 Sep 19.

Supplemental Content

Support Center